Arbutus Biopharma Net Worth
Arbutus Biopharma Net Worth Breakdown | ABUS |
Arbutus Biopharma Net Worth Analysis
Arbutus Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Arbutus Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Arbutus Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Arbutus Biopharma's net worth analysis. One common approach is to calculate Arbutus Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Arbutus Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Arbutus Biopharma's net worth. This approach calculates the present value of Arbutus Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Arbutus Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Arbutus Biopharma's net worth. This involves comparing Arbutus Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Arbutus Biopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Arbutus Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Arbutus Biopharma's net worth research are outlined below:
| Arbutus Biopharma generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 18.14 M. Net Loss for the year was (72.85 M) with loss before overhead, payroll, taxes, and interest of (56.05 M). | |
| Arbutus Biopharma Corp currently holds about 150.2 M in cash with (85.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0. | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Jim Cramer onArbutus Biopharma Corporation It Loses Money |
Arbutus Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Arbutus Biopharma Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arbutus Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Arbutus Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arbutus Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arbutus Biopharma Corp backward and forwards among themselves. Arbutus Biopharma's institutional investor refers to the entity that pools money to purchase Arbutus Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rubric Capital Management Lp | 2024-09-30 | 1.7 M | Advisor Group Holdings, Inc. | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.2 M | Hudson Bay Capital Management Lp | 2024-09-30 | 1 M | Corbin Capital Partners Lp | 2024-09-30 | 853.3 K | Saba Capital Management, Lp | 2024-09-30 | 676.4 K | Woodline Partners Lp | 2024-09-30 | 668.2 K | Boothbay Fund Management, Llc | 2024-09-30 | 612.3 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 21.7 M | Whitefort Capital Management, Lp. | 2024-09-30 | 12.9 M |
Follow Arbutus Biopharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 606.37 M.Market Cap |
|
Project Arbutus Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (0.79) | (0.75) |
When accessing Arbutus Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Arbutus Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Arbutus Biopharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Arbutus Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arbutus Biopharma Corp. Check Arbutus Biopharma's Beneish M Score to see the likelihood of Arbutus Biopharma's management manipulating its earnings.
Evaluate Arbutus Biopharma's management efficiency
Arbutus Biopharma Corp has return on total asset (ROA) of (0.3283) % which means that it has lost $0.3283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6781) %, meaning that it created substantial loss on money invested by shareholders. Arbutus Biopharma's management efficiency ratios could be used to measure how well Arbutus Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2025. Return On Capital Employed is likely to drop to -0.61 in 2025. At this time, Arbutus Biopharma's Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 165.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 13.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.73 | 0.70 | |
| Tangible Book Value Per Share | 0.73 | 0.70 | |
| Enterprise Value Over EBITDA | (6.44) | (6.12) | |
| Price Book Value Ratio | 4.50 | 8.02 | |
| Enterprise Value Multiple | (6.44) | (6.12) | |
| Price Fair Value | 4.50 | 8.02 | |
| Enterprise Value | 357.6 M | 375.5 M |
Arbutus Biopharma Corp benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Enterprise Value Revenue 71.1993 | Revenue | Quarterly Revenue Growth (0.71) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arbutus Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arbutus Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arbutus Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arbutus Biopharma Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 16th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 8th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Arbutus Biopharma Earnings per Share Projection vs Actual
Arbutus Biopharma Corporate Management
| BA Esq | General Officer | Profile | |
| Gaston Picchio | Chief Officer | Profile | |
| Lisa Caperelli | Vice Relations | Profile | |
| David CPA | CFO Officer | Profile | |
| William Collier | CEO Pres | Profile | |
| Elizabeth Howard | Gen VP | Profile |
Already Invested in Arbutus Biopharma Corp?
The danger of trading Arbutus Biopharma Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arbutus Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arbutus Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arbutus Biopharma Corp is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.